280 related articles for article (PubMed ID: 22262331)
1. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
2. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
4. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Gronchi A
Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant therapy for primary GIST.
Eisenberg BL; Smith KD
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S3-8. PubMed ID: 21116626
[TBL] [Abstract][Full Text] [Related]
7. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
8. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
9. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
10. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
11. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
12. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
13. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
[TBL] [Abstract][Full Text] [Related]
15. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
[TBL] [Abstract][Full Text] [Related]
17. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
18. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Eisenberg BL; Judson I
Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments.
Reynoso D; Trent JC
Curr Opin Oncol; 2010 Jul; 22(4):330-5. PubMed ID: 20520542
[TBL] [Abstract][Full Text] [Related]
20. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]